MAP3K19 inhibition protected mice from bleomycin-induced pulmonary fibrosis when administered prophylactically (A-C).

<p>C57Bl/6J mice had saline (n = 5 mice) or bleomycin instilled intra-tracheally (i.t.) on Day 0 and for the prophylactic treatment, received either the vehicle control (n = 12) or Compound A (10 mg/kg; n = 12) delivered daily orally, dexamethasone administered intra-peritoneally (i.p.) every other day (3 mg/kg, n = 12), or no treatment (n = 5). On day 14, the mice were sacrificed, and histological criteria were used to assess (A) the pulmonary fibrosis determined using the Ashcroft scale [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0154874#pone.0154874.ref031" target="_blank">31</a>], (B) the collagen deposition was scored using the method described by Faress et al. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0154874#pone.0154874.ref032" target="_blank">32</a>], and (C) the soluble collagen content in lung homogenates was determined using a Sircol assay. Values shown are the mean ± SEM.</p>